PureSea (Ascophyllum nodosum)

PureSea is a standardized extract of Ascophyllum nodosum, a North Atlantic brown seaweed containing alginates, fucoidans, and naturally occurring iodine. Its bioactive polysaccharides — particularly fucoidans with 52.1% fucose content — are theorized to modulate thyroid hormone precursor availability via iodine delivery, though clinical human evidence remains limited.

Origin & History

PureSea is a branded extract derived from Ascophyllum nodosum, a brown seaweed harvested from coastal regions of Ireland, Scotland, and France. It is produced through water-based extraction involving blending dried seaweed meal with mild acidification, followed by filtration, ultrafiltration, and spray-drying to yield a powder with approximately 17% extraction yield.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the research. Ascophyllum nodosum has been used in modern industrial extraction since approximately 2011 and as agricultural biostimulants, but no traditional medicine applications are mentioned.

Health Benefits

• No clinical health benefits documented - research focuses only on extraction methods and physicochemical properties
• Contains alginates and fucoidans (52.1% fucose content) - compounds with theoretical bioactive potential but no human evidence
• Rich in minerals including potassium (41.2 g/kg) and sodium (51.3 g/kg) - nutritional content only, no therapeutic claims supported
• Agricultural biostimulant properties demonstrated for pest reduction on crops - not applicable to human health
• Gelling properties of alginate fraction characterized - relevant for industrial applications only

How It Works

Ascophyllum nodosum provides inorganic iodine, which is taken up by thyroid follicular cells via the sodium-iodide symporter (NIS) and incorporated into thyroglobulin through thyroid peroxidase (TPO)-mediated oxidation, forming T3 and T4 precursors. Its fucoidans — sulfated polysaccharides — may interact with selectin receptors and modulate inflammatory cytokine cascades, theoretically influencing autoimmune thyroid activity. Alginates within the extract may slow gastrointestinal absorption of iodine, potentially offering a more sustained release profile compared to potassium iodide supplements.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for PureSea or Ascophyllum nodosum extract in the research. Available studies focus exclusively on extraction methodology, structural analysis of polysaccharides, and agricultural applications without any PMIDs for human health research.

Clinical Summary

No published randomized controlled trials have evaluated PureSea specifically as a thyroid health intervention in human subjects; available research is largely confined to extraction methodology, physicochemical characterization, and in vitro bioactivity assays. A limited number of observational studies on general Ascophyllum nodosum consumption suggest improvements in postprandial glycemia, but these findings are not directly applicable to thyroid endpoints. The seaweed's high potassium content (41.2 g/kg) and iodine levels are well-documented analytically, but translational dose-response data in clinical populations are absent. Overall, the evidence base for PureSea as a thyroid supplement is preclinical and preliminary, warranting cautious interpretation.

Nutritional Profile

PureSea (Ascophyllum nodosum) is a brown seaweed ingredient with a complex nutritional matrix. Carbohydrates dominate the dry weight, primarily as structural polysaccharides: alginates (20–30% dry weight) and fucoidans (sulfated fucose-rich polysaccharides with 52.1% fucose content). Mannitol contributes additional soluble carbohydrate content. Protein content ranges 5–15% dry weight depending on harvest season, providing a modest amino acid contribution. Lipid content is low (~1–3% dry weight) but includes polyunsaturated fatty acids such as EPA (eicosapentaenoic acid) in minor quantities. Mineral content is notably high: potassium at 41.2 g/kg dry weight and sodium at 51.3 g/kg dry weight are the dominant electrolytes; iodine is present at agriculturally significant but variable concentrations (typically 400–700 mg/kg dry weight), warranting attention in human consumption contexts. Magnesium, calcium, and iron are also present at trace-to-moderate levels. Bioactive compounds include fucoidans (with sulfation patterns linked to theoretical bioactivity), laminarin, and phlorotannins (polyphenolic compounds). Dietary fiber content is substantial, largely from alginic acid and fucoidan fractions, estimated at 30–45% dry weight. Vitamins include modest levels of B vitamins (B1, B2, B12 trace) and vitamin C, though concentrations are variable and processing-dependent. Bioavailability of minerals may be reduced due to alginate binding; iodine bioavailability is relatively high. Human absorption data for fucoidans and phlorotannins remains limited.

Preparation & Dosage

No clinically studied dosage ranges are available as no human clinical studies have been conducted. Commercial forms include spray-dried powders, but no standardization for fucoidan or alginate content is specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Iodine, Selenium, L-Tyrosine, Vitamin D3, Ashwagandha

Safety & Interactions

High iodine intake from Ascophyllum nodosum can paradoxically inhibit thyroid hormone synthesis via the Wolff-Chaikoff effect, posing particular risk to individuals with pre-existing hypothyroidism, Hashimoto's thyroiditis, or Graves' disease. Individuals taking levothyroxine, anti-thyroid drugs such as methimazole, or amiodarone should avoid unsupervised use due to potential iodine-drug interactions that may destabilize thyroid hormone levels. The elevated potassium content (41.2 g/kg dry weight) represents a contraindication concern for individuals with hyperkalemia or those on potassium-sparing diuretics or ACE inhibitors. Safety during pregnancy and lactation has not been established in controlled studies, and excess iodine supplementation during pregnancy carries risk of neonatal thyroid suppression.